Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03716102 · ClinicalTrials.gov registry record · NA

OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study

A NA study of Acute Coronary Syndrome, sponsored by Svelte Medical Systems.

Active
Registry status
NA
Development phase
12
Enrollment target
2
Study locations

NCT03716102 is a NA study of Acute Coronary Syndrome that is active but no longer recruiting, run by Svelte Medical Systems. The registered enrollment target is 12 participants, below the 2,722-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03716102, a NA study of Acute Coronary Syndrome, is active but no longer recruiting, sponsored by Svelte Medical Systems.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
2
Study locations

Study Summary

To evaluate the pharmacokinetic parameters of sirolimus release from the Svelte DES.

Conditions Studied

Interventions

  • DEVICE PCI with implantation with DES

Study Locations (2)

Arizona

  • Scottsdale Healthcare - Scottsdale

Michigan

  • Northern Michigan Hospital d.b.a McLaren Northern Michigan - Petoskey

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2018-11-21
Est. Completion 2021-07-15
Phase NA

Sponsor

Svelte Medical Systems

2 total trials

What the Registry Record Tells You About NCT03716102

The ClinicalTrials.gov registry entry for NCT03716102 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,722-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (100% lower). The listed sponsor is Svelte Medical Systems, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which PCI with implantation with DES is the first listed.

NCT03716102 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Michigan.

Frequently Asked Questions

What is clinical trial NCT03716102 about?

NCT03716102 is a clinical study titled "OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study". To evaluate the pharmacokinetic parameters of sirolimus release from the Svelte DES.

What is the current status of trial NCT03716102?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2018-11-21. Estimated completion is 2021-07-15.

What conditions does trial NCT03716102 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT03716102?

The interventions under investigation include: PCI with implantation with DES (DEVICE).

Who is sponsoring clinical trial NCT03716102?

This trial is sponsored by Svelte Medical Systems, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03716102 being conducted?

This trial has 2 study locations across Arizona, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.